{"Title": "Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy", "Year": 2016, "Source": "Immunity", "Volume": "45", "Issue": 6, "Art.No": null, "PageStart": 1181, "PageEnd": 1183, "CitedBy": 4, "DOI": "10.1016/j.immuni.2016.12.004", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85006699088&origin=inward", "Abstract": "\u00a9 2016 Elsevier Inc.Immune checkpoint blockade (ICB) is revolutionizing cancer medicine, yet the molecular basis of resistance remains unclear. In a recent issue of Cell, Benci et al. (2016) demonstrate that sustained interferon signaling is central to the development of PD-L1-dependent and -independent resistance to ICB.", "AuthorKeywords": null, "IndexKeywords": ["Antibodies, Monoclonal", "Antigens, CD274", "Humans", "Immunotherapy", "Neoplasms", "Programmed Cell Death 1 Receptor"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85006699088", "SubjectAreas": [["Immunology and Allergy", "MEDI", "2723"], ["Immunology", "IMMU", "2403"], ["Infectious Diseases", "MEDI", "2725"]], "AuthorData": {"57206292773": {"Name": "Reading J.", "AuthorID": "57206292773", "AffiliationID": "60109234, 60022148", "AffiliationName": "Cancer Immunology Unit, UCL Cancer Institute, University College London"}, "12762916100": {"Name": "Quezada S.", "AuthorID": "12762916100", "AffiliationID": "60109234, 60022148", "AffiliationName": "Cancer Immunology Unit, UCL Cancer Institute, University College London"}}}